Skip to main navigation Skip to search Skip to main content

Rational use of mucoactive medications to treat pediatric airway disease

  • R. S. N. Linssen
  • , J. Ma
  • , R. A. Bem
  • , B. K. Rubin*
  • *Corresponding author for this work
  • University of Amsterdam
  • Virginia Commonwealth University

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Many airway diseases in children, notably bronchiolitis, cystic fibrosis (CF), non-CF bronchiectasis including primary ciliary dyskinesia, pneumonia, and severe asthma are associated with retention of airway secretions. Medications to improve secretions clearance, the mucoactive medications, are employed to treat these diseases with varying degrees of success. This manuscript reviews evidence for the use of these medications and future directions of study.
Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalPaediatric respiratory reviews
Volume36
Early online date2020
DOIs
Publication statusPublished - Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Airway diseases
  • Cystic fibrosis
  • Dornase
  • Mucoactive medications
  • Mucolytics
  • Sputum

Fingerprint

Dive into the research topics of 'Rational use of mucoactive medications to treat pediatric airway disease'. Together they form a unique fingerprint.

Cite this